Champions Oncology Files 10-Q
Ticker: CSBR · Form: 10-Q · Filed: Sep 13, 2024 · CIK: 771856
| Field | Detail |
|---|---|
| Company | Champions Oncology, INC. (CSBR) |
| Form Type | 10-Q |
| Filed Date | Sep 13, 2024 |
| Risk Level | low |
| Pages | 15 |
| Reading Time | 18 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, biotechnology
TL;DR
Champions Oncology filed its 10-Q for Q3 2024. Check financials.
AI Summary
Champions Oncology, Inc. filed its 10-Q for the period ending July 31, 2024. The company, previously known as Champions Biotechnology, Inc., is in the biological products sector. Its fiscal year ends on April 30th, and its principal business address is in Baltimore, MD.
Why It Matters
This filing provides investors with an update on the company's financial performance and operational status for the latest fiscal quarter.
Risk Assessment
Risk Level: low — This is a standard quarterly filing providing financial information, not indicating immediate significant risk.
Key Players & Entities
- CHAMPIONS ONCOLOGY, INC. (company) — Filer
- CHAMPIONS BIOTECHNOLOGY, INC. (company) — Former company name
- BALTIMORE, MD (location) — Business address
- 20240731 (date) — Period of report
FAQ
What is the reporting period for this 10-Q filing?
The Conformed Period of Report is 20240731, meaning the filing covers the period ending July 31, 2024.
What is the company's Standard Industrial Classification (SIC) code?
The SIC code is [2836], which corresponds to Biological Products (No Diagnostic Substances).
When is Champions Oncology's fiscal year end?
The company's fiscal year ends on 0430 (April 30th).
What was the company formerly known as?
The company was formerly known as CHAMPIONS BIOTECHNOLOGY, INC. and CHAMPIONS SPORTS INC.
Where is the company's business address?
The business address is 855 N. WOLFE STREET, SUITE 619, BALTIMORE, MD 21205.
Filing Stats: 4,552 words · 18 min read · ~15 pages · Grade level 15.8 · Accepted 2024-09-13 13:07:33
Key Financial Figures
- $0.001 — ich Registered Common Stock, par value $0.001 per share CSBR The Nasdaq Stock Market
Filing Documents
- csbr-20240731.htm (10-Q) — 637KB
- csbrq1731202410-qex311.htm (EX-31.1) — 11KB
- csbrq1731202410-qex312.htm (EX-31.2) — 11KB
- csbrq1731202410-qex321.htm (EX-32.1) — 8KB
- 0001628280-24-040312.txt ( ) — 4426KB
- csbr-20240731.xsd (EX-101.SCH) — 33KB
- csbr-20240731_cal.xml (EX-101.CAL) — 54KB
- csbr-20240731_def.xml (EX-101.DEF) — 118KB
- csbr-20240731_lab.xml (EX-101.LAB) — 483KB
- csbr-20240731_pre.xml (EX-101.PRE) — 313KB
- csbr-20240731_htm.xml (XML) — 523KB
- FINANCIAL INFORMATION
PART I - FINANCIAL INFORMATION
Financial Statements
Item 1. Financial Statements. Condensed Consolidated Balance Sheets as of July 31, 2024 (unaudited) and April 30, 202 4 4 Unaudited Condensed Consolidated Statements of Operations for the Three Months Ended July 31, 2024 and 2023 5 Unaudited Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficiency) for the Three Months Ended July 31, 2024 and 2023 6 Unaudited Condensed Consolidated Statements of Cash Flows for the Three Months Ended July 31, 2024 and 2023 7 Notes to Unaudited Condensed Consolidated Financial Statements 8
Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 19
Quantitative and Qualitative Disclosures About Market Risk
Item 3. Quantitative and Qualitative Disclosures About Market Risk 22
Controls and Procedures
Item 4. Controls and Procedures 22
- OTHER INFORMATION
PART II - OTHER INFORMATION
Legal Proceedings
Item 1. Legal Proceedings 24
Risk Factors
Item 1A. Risk Factors 24
Unregistered Sales of Equity Securities and Use of Proceeds
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 24
Defaults Upon Senior Securities
Item 3. Defaults Upon Senior Securities 24
Mine Safety Disclosures
Item 4. Mine Safety Disclosures 24
Other Information
Item 5. Other Information 24
Exhibits
Item 6. Exhibits 25 3
– FINANCIAL INFORMATION
PART I – FINANCIAL INFORMATION
Financial Statements
Item 1. Financial Statements CHAMPIONS ONCOLOGY, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Dollars in Thousands) July 31, 2024 April 30, 2024 (unaudited) ASSETS Current assets: Cash and cash equivalents $ 2,892 $ 2,618 Accounts receivable, net 9,032 9,526 Prepaid expenses and other current assets 1,254 1,495 Total current assets 13,178 13,639 Operating lease right-of-use assets, net 5,963 6,252 Property and equipment, net 5,272 5,721 Other long-term assets 185 185 Goodwill 335 335 Total assets $ 24,933 $ 26,132 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 5,235 $ 5,800 Accrued liabilities 2,097 2,160 Current portion of operating lease liabilities 1,369 1,337 Other current liability 151 150 Deferred revenue 10,312 12,094 Total current liabilities 19,164 21,541 Non-current operating lease liabilities 5,738 6,093 Other non-current liabilities 363 401 Total liabilities $ 25,265 $ 28,035 Stockholders' equity (deficiency): Common stock, $ .001 par value; 200,000,000 shares authorized; 13,714,099 and 13,714,099 shares issued; and 13,593,766 and 13,593,766 outstanding as of July 31, 2024 and April 30, 2024, respectively 14 14 Treasury stock, at cost ( 708 ) ( 708 ) Additional paid-in capital 83,642 83,384 Accumulated deficit ( 83,280 ) ( 84,593 ) Total stockholders' equity (deficiency) ( 332 ) ( 1,903 ) Total liabilities and stockholders' equity (deficiency) $ 24,933 $ 26,132 The accompanying notes are an integral part of these Condensed Consolidated Financial Statements. 4 CHAMPIONS ONCOLOGY, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Dollars in Thousands, Except Per Share Amounts) Three Months Ended July 31, 2024 2023 Oncology services revenue $ 14,061 $ 12,561 Costs and operating expenses: Cost of oncology services 7,072 7,684 Research and development 1,454 2,793 Sales and marketing 1,679 1,696 General and administrative 2,527 2,940 Total costs and